Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Teva
UBS
QuintilesIMS
Harvard Business School

Generated: March 21, 2019

DrugPatentWatch Database Preview

ZONTIVITY Drug Profile

« Back to Dashboard

When do Zontivity patents expire, and when can generic versions of Zontivity launch?

Zontivity is a drug marketed by Aralez Pharms and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and sixty-two patent family members in thirty-six countries.

The generic ingredient in ZONTIVITY is vorapaxar sulfate. One supplier is listed for this compound. Additional details are available on the vorapaxar sulfate profile page.

Summary for ZONTIVITY
Drug patent expirations by year for ZONTIVITY
Generic Entry Opportunity Date for ZONTIVITY
Generic Entry Date for ZONTIVITY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for ZONTIVITY
Synonyms for ZONTIVITY
2-[(E)-2-{(3R,3aS,4S,4aR,7R,8aR,9aR)-7-[(ethoxycarbonyl)amino]-3-methyl-1-oxododecahydronaphtho[2,3-c]furan-4-yl}ethenyl]-5-(3-fluorophenyl)pyridinium hydrogen sulfate
705260-08-8
AKOS030524402
AN-9455
Carbamic acid, ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((1E)-2-(5-(3-fluorophenyl)-2-pyridinyl)ethenyl)dodecahydro-1-methyl-3-oxonaphtho(2,3-c)furan-6-yl)-, ethyl ester, sulfate (1:1)
CHEBI:83314
CHEMBL2107386
D09766
ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate sulfate
ethyl [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl}-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl]carbamate sulfate
ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f]isobenzofuran-6-yl]carbamate; sulfuric acid
ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate;sulfuric acid
EX-A1149
IN66038E6C
KB-80525
MFCD16038877
MolPort-046-033-533
N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-Fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]carbamic Acid Ethyl Ester Sulfate
Sch 530348
SCH 530348 H2SO4 Salt
SCH 530348 sulfate; Vorapaxar sulfate; MK5348
SCH 530348|||MK-5348
UNII-IN66038E6C
vorapaxar monosulfate
VORAPAXAR SULFATE
Vorapaxar sulfate (JAN/USAN)
Vorapaxar sulfate [USAN]
Zontivity (TN)

US Patents and Regulatory Information for ZONTIVITY

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Aralez Pharms ZONTIVITY vorapaxar sulfate TABLET;ORAL 204886-001 May 8, 2014 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for ZONTIVITY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1495018 CR 2015 00037 Denmark ➤ Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING VORAPAXARSULPHATE; REG. NO/DATE: EU/1/14/976/001-06 20150119
1495018 1590037-6 Sweden ➤ Sign Up PRODUCT NAME: VORAPAXAR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF; REG. NO/DATE: EU/1/14/976/001 20150121
1495018 PA2015027,C1495018 Lithuania ➤ Sign Up PRODUCT NAME: VORAPAKSARAS; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150119
1495018 218 50011-2015 Slovakia ➤ Sign Up PRODUCT NAME: VORAPAXARIUMSULFAT; REGISTRATION NO/DATE: EU/1/14/976/001 - EU/1/14/976/006 20150121
Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Covington
Cantor Fitzgerald
Harvard Business School
Farmers Insurance
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.